{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:40:05Z","timestamp":1750138805776,"version":"3.41.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Farmaceutica Spain SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.farma.2024.05.016","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:29:36Z","timestamp":1720931376000},"page":"117-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment adherence to oral chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: Protocol for a hospital pharmacy-based real-world study"],"prefix":"10.1016","volume":"49","author":[{"given":"Irene","family":"Mangues-Bafalluy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Bern\u00e1rdez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Mart\u00ednez-Sesmero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Navarro-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Rosa","family":"Rubio-Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Mart\u00edn-Conde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2024.05.016_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.909948","article-title":"National trends in the use of oral chemotherapy over 13 years","volume":"13","author":"Moreira","year":"2022","journal-title":"Front Pharmacol"},{"author":"IQVIA Institute","key":"10.1016\/j.farma.2024.05.016_bb0010"},{"issue":"Suppl 3","key":"10.1016\/j.farma.2024.05.016_bb0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN task force report: oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.farma.2024.05.016_bb0020","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.farma.2024.05.016_bb0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1188\/10.CJON.447-453","article-title":"Perceptions and experiences of patients receiving oral chemotherapy","volume":"14","author":"Simchowitz","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.farma.2024.05.016_bb0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","article-title":"A systematic review of adherence to oral antineoplastic therapies","volume":"21","author":"Greer","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.farma.2024.05.016_bb0035","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2024.05.016_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016982","article-title":"Economic impact of medication non-adherence by disease groups: a systematic review","volume":"8","author":"Cutler","year":"2018","journal-title":"BMJ Open"},{"author":"World Health Organization","key":"10.1016\/j.farma.2024.05.016_bb0045"},{"key":"10.1016\/j.farma.2024.05.016_bb0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2024.05.016_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2024.05.016_bb0060","first-page":"79","article-title":"The Spanish version of EuroQol: a description and its applications. European Quality of Life scale","volume":"112","author":"Badia","year":"1999","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.farma.2024.05.016_bb0065","first-page":"127","article-title":"El cuestionario de Calidad de Vida para c\u00e1ncer de pulm\u00f3n de la EORTC QLQ-LC13. Estudio de validaci\u00f3n para nuestro pa\u00eds\/The EORTC QLC-LC13 quality of life for lung cancer patients. Validation study for Spain","volume":"23","author":"Arraras","year":"2000","journal-title":"Oncolog\u00eda (Barc)"},{"key":"10.1016\/j.farma.2024.05.016_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.aprim.2010.11.022","article-title":"Perception in chronic illnesses: linguistic validation of the revised Illness Perception Questionnaire and the Brief Illness Perception Questionnaire for a Spanish population","volume":"44","author":"Pacheco-Huergo","year":"2012","journal-title":"Aten Primaria"},{"key":"10.1016\/j.farma.2024.05.016_bb0075","first-page":"767","article-title":"Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test","volume":"10","author":"Val Jim\u00e9nez","year":"1992","journal-title":"Aten Primaria"},{"key":"10.1016\/j.farma.2024.05.016_bb0080","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1524-4733.2008.00323.x","article-title":"Development and validation of the \"Treatment Satisfaction with Medicines Questionnaire\" (SATMED-Q)","volume":"11","author":"Ruiz","year":"2008","journal-title":"Value Health"},{"author":"Grupo Espa\u00f1ol de C\u00e1ncer de Pulm\u00f3n","key":"10.1016\/j.farma.2024.05.016_bb0085"},{"key":"10.1016\/j.farma.2024.05.016_bb0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pst.1901","article-title":"Calculation of confidence intervals for a finite population size","volume":"18","author":"Julious","year":"2019","journal-title":"Pharm Stat"},{"key":"10.1016\/j.farma.2024.05.016_bb0095","first-page":"18","article-title":"Medication experience and adherence to oral chemotherapy: a qualitative study of patients' and health professionals' perspectives","author":"Talens","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.farma.2024.05.016_bb0100","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1007\/s00520-020-05469-y","article-title":"A review of factors influencing non-adherence to oral antineoplastic drugs","volume":"28","author":"Skrabal Ross","year":"2020","journal-title":"Support Care Cancer"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:09:43Z","timestamp":1750136983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1130634324000989"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.05.016","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment adherence to oral chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: Protocol for a hospital pharmacy-based real-world study","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}